Curated News
By: NewsRamp Editorial Staff
August 21, 2025
HeartBeam Secures New Patents to Revolutionize Portable Cardiac Monitoring
TLDR
- HeartBeam's new patents strengthen its competitive edge in cardiac monitoring, offering investors and partners exclusive access to innovative 3D ECG technology for market leadership.
- HeartBeam's patented 3D ECG platform captures 12-lead electrical signals from three dimensions, enabling portable, cable-free cardiac monitoring outside medical facilities with actionable insights.
- HeartBeam's technology improves global cardiac care by enabling accessible, remote heart health monitoring, empowering patients and physicians to enhance outcomes and save lives.
- HeartBeam now holds over 20 patents for its groundbreaking cable-free 3D ECG, revolutionizing how heart signals are captured and analyzed anywhere.
Impact - Why it Matters
This development matters because cardiovascular diseases remain a leading cause of death globally, with millions experiencing cardiac events outside medical facilities. HeartBeam's technology enables early detection and remote monitoring of heart conditions, potentially saving lives by providing critical data to healthcare providers in real-time. For patients, this means greater accessibility to cardiac care, reduced hospital visits, and improved management of chronic conditions. The advancement also represents significant progress in telemedicine and wearable health technology, addressing the growing demand for decentralized healthcare solutions that empower individuals to take control of their heart health from anywhere.
Summary
HeartBeam Inc. (NASDAQ: BEAT), a pioneering medical technology company, has significantly strengthened its position in the cardiac monitoring sector by securing two new U.S. patents that enhance its intellectual property portfolio. These patents bolster the company's innovative 3D ECG platform, which aims to deliver powerful, personalized heart health insights outside traditional medical facilities. With these additions, HeartBeam now holds more than 20 U.S. and international patents, with additional applications pending, solidifying its leadership in transforming cardiac care through portable technology.
According to HeartBeam CEO Robert Eno, the company's vision is to make cardiac monitoring and diagnosis more accessible for patients and physicians beyond clinical settings. The groundbreaking 3D ECG technology enables the first-ever cable-free 12-lead ECG capable of capturing the heart's electrical signals from three dimensions, providing actionable intelligence wherever the patient is located. This advancement allows physicians to identify cardiac health trends and acute conditions remotely, directing patients to appropriate care and redefining the future of cardiac health management. For more details, visit the full article at https://ibn.fm/RgRun.
The news was distributed through BioMedWire, a specialized communications platform focused on biotechnology and biomedical sciences, which is part of the Dynamic Brand Portfolio at IBN. This platform ensures wide dissemination to investors, influencers, and the general public, enhancing recognition and brand awareness for companies like HeartBeam. With its growing patent portfolio and innovative approach, HeartBeam continues to push the boundaries of cardiac care technology, making significant strides in portable health monitoring solutions that could benefit millions worldwide.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, HeartBeam Secures New Patents to Revolutionize Portable Cardiac Monitoring
